Abnormal Ca²⁺ signaling and elevated concentration of intracellular free Ca²⁺ are the basic pathophysiological events involved in various diseases. As a Ca²⁺ antagonist, Tet can inhibit extracellular Ca²⁺ entry, intervene in the distribution of intracellular Ca²⁺, maintain intracellular Ca²⁺ homeostasis, and then disrupt the pathological processes. As shown in whole cell patch-clamp recordings, Tet blocked bovine chromaffin cells voltage-operated Ca²⁺ channel current in a time- and concentration-dependently manner. In rat phaeochromocytoma PC 12 cells, 100 μmol·L¯¹ Tet abolished high K⁺ (30 mmol•L¯¹) -induced sustained increase in cytoplasmic Ca²⁺ concentration, inhibit bombesin-induced inositol triphosphate accumulation in NIH/3T3 fibroblast and abolish Ca²⁺ entry[1]. In rat glioma C6 cells, studied with fluorometric ratio method, Tet did not affect the resting cytoplasmic Ca²⁺ concentration, but it inhibited IP3 accumulation and the sustained and peak elevation of cytoplasmic Ca²⁺ concentration induced by bombesin and thapsigargin, a microsomal Ca²⁺-ATPase inhibitor, in a dose-dependent manner. The dose of Tet needed to abolish the sustained and peak elevation of cytoplasmic Ca²⁺ concentration induced by bombesin and thapsigargin was 30 μmol•L¯¹[2]. Bickmeyer et al[3] demonstrated that NG108-15 cells treated with 100 μM Tet for seven minutes could block voltage-dependent Ca²⁺ entry induced by depolarization with 50 mM KCl. Tet could block non-voltage-operated Ca²⁺ entry activated by intracellular Ca²⁺ store depletion induced by thapsigargin and could release intracellular Ca²⁺ in HL-60 cells, and could therefore increase concentration of intracellular free Ca²⁺, elicit therapeutic effects. We have previ ously demonstrated that Tet could concentration-dependently block extracellular Ca²⁺ entry into hepatocytes, promote mitochondria Ca²⁺-uptake, and inhibit Ca²⁺-mobilizing from mitochondria. However, the blockade of Ca²⁺ channel played the most important role in maintaining Ca²⁺ homeostasis, but not intracellular Ca²⁺ distribution.

In the presence of extracellular Ca²⁺ (1.3 μmol•L¯¹), glutamate, serotonin and histamine significantly increased the intracellular Ca²⁺ concentration in a dose-dependent manner. Thirty μmol•L¯¹ Tet significantly inhibited the increase in intracellular Ca²⁺ concentration induced by glutamate, serotonin and histamine by 28.0%, 46.8% and 29.0%. In Ca²⁺ free Hanks’ solution, Tet did not produce a significant inhibitory effect on the increase in intracellular Ca²⁺ concentration caused by serotonin and histamine. These results indicated that Tet conducted blocking of Ca²⁺ influx from the extracellular site via NMDA, 5-HT₂ and histamine type I receptor-operated Ca²⁺ channels and has no obvious effect on the Ca²⁺ release from intracellular Ca²⁺ stores[4]. In addition, Tet also inhibited extracellular Ca²⁺ entry and intracellular Ca²⁺ mobilization induced by norepinhpr ine and angiotonin II via corresponding receptor respectively[3,5]. Taking together, in different tissues and different kinds of cells, Tet may block the Ca²⁺ channel through different mechanisms. It can block the voltage- and/or receptor-operated Ca²⁺ channel. Nevertheless, in some kind of carcinoma cells, Tet does not affect Ca²⁺ channel, but promote Ca²⁺ release from intracellular stores and elevate the cytosolic free Ca²⁺ concentration.

Clinically, Stephania tetrandra S. Moore has been thought to be effective in treating autoimmune diseases such as rheumatoid arthritis and systemic lupus erythe matosus. Tet, the active ingredient isolated from Stephania tetrandra S. Moore, has potential immunomodul ating and anti-inflammatory effects. T-lymphocyte splay a critical role as autoactive and pathogenic population in autoimmune and inflammatory diseases. Some experimental data showed that, through down-regulating the protein kinase C (PKC) signaling, interleukin-2 secretion and the expression of the T cell activation antigen (CD71), Tet inhibited phobol 12-myristate 13-acetate (PMA)+ionomycin-induced T cell proliferation dependent on interleukin-2 receptor alpha chain and CD69, such an action was unrelated to Ca²⁺ channel blockade[6]. Tet (0.1-10 μmol•L¯¹) significantly inhibited neutrophil-monocyte chemotactic factor-1 upregulation and adhesion to fibrinogen induced by N-formyl-methionyl-leucyl-phenylalanim ne and PMA. Tet at 0.1-100 μmol•L¯¹ caused dose- and time-dependent loss of cell viability of mouse peritoneal macrophages, guinea-pig alveolar macrophages and mouse macrophage-like J774 cells, reduced production of oxyg en free radical oxygen, down-regulated synthesis and release of some pro-inflammatory cytokines[7,8].

Nuclear transcription factor kappa B (NF-kappa B) is a multiprotein complex which regulates a variety of genes concerned with immunity and inflammation. For the alveolar macrophages, Tet could inhibit the activation of their NF-kappa B and NF-kappa B-dependent reporter gene expression induced by endotoxin, PMA, and silica in a dose-dependent manner. Western blot analysis suggested that the inhibitory effects of tetrandrine on NF-kappa B activation could be attributed to its ability to suppress signal-induced degradation of I kappa B alpha, a cytoplasmic inhibitor of the NF-kappa B transcription factor[7,9].

To induce tumor cell apoptosis is one of the important chemo-therapeutic strategies for malignent tumors. Tet inhibited both proliferation and clonogenicity of human leukemic U937 cells at an optimal concentration of 2.5 mg•L¯¹. The characteristic morphological changes of apoptosis were observed under light microscopy and DNA fragmentation was noted by gel electrophoresis in these cells. Moreover, flow-cytometric detection of surface phosphatidyl serine expression of cells after treatment with Tet confirmed the induction of apoptosis in these cells[10]. Tet concentration-dependently inhibited the proliferation of human leukemic HL-60 cells. Morphological observation and DNA analysis revealed that Tet caused cell shrinkage with the formation of apoptotic bodies, and showed clear evidence of DNA fragmentation[11]. Tet was found to induce pronounced morphological changes characteristic of apopt osis and extensive DNA fragmentation in the human BM13674 cell line 8 h after treatment[12]. The induction of apoptosis by Tet was much more rapid in CEM-C7 cells (4 h) than in the same cells treated with glucocort icoids (40 h), and did not require de novo protein synthesis[13]. These results indicate that Tet may have value as an anti-neoplastic agent.

The occurrence of MDR to chemotherapeutic drugs is a major problem for successful cancer treatment. The overexpression of cell membrane P-glycoprotein (P-gp) is one of the major mechanisms of MDR. P-gp pumps antitumor drugs out of tumor cells, causing drug resistance.

Tet (3 μmol•L¯¹) reduced the paclitaxel concentration required to achieve 50% inhibition of cell growth (EC50) of HCT15 (P-gp-positive) cells about 3100-fold, and also reduced the EC50 value of actinomycin D about 36.0-fold in the cells. Meanwhile, Tet had no effect on the cytotoxic ity of the drugs to SK-OV-3 (P-gp-negative) cells[14]. The non-cytotoxic concentrations of Tet potentiated the growth-inhibitory actions of doxorubicin (Dox) in the Har-resistant HL60 cells. The colony formation efficencies were reduced from 60% by Dox to 0.2% by Tet + Dox. Retardation of the G2M phase cells was increased. But Tet did not potentiate Dox cytotoxity in the sensitive HL60 cells. Dox accumulation in the harringtonine-resistant HL60 cells treated by with was increased. These results indicated that Tet enhanced the cytotoxicity of MDR-related drugs via modulation of P-gp[15]. In addition, Tet could also inhibit platelet- activating factor-induced human platelet aggregation and decrease thromboxane B2 production and thrombus formation[16].

Hepatocyte lesions are common and very important clinically[17-21]. Chen et al[22] observed the effects of Tet on hepatocytic injury induced by CCl₄. The result showed that, compared with control group, Tet (1-1000 nmol•L¯¹) increased viability of liver cell (from 71% to 72%-89%), reduced lactate dehydrogenase release, and malondialdehyde (MDA) formation. Tet prevented the increase of the intracellular Ca²⁺ concentration and the attenuation of the membrane microflow of liver cells. Tet (30 mg•kg¯¹•d¯¹via gavage for two weeks) could markedly re duce the elevation of serum alanine aminotransferase, alkaline phosphatatase and MDA induced by azathioprine. The level of reductive glutathione and SOD were not different from the normal control group. Histological changes in the Tet-treated group were slight[23]. The protective effect on CCl₄- or azathioprine-injured hepatocytes may be elicited by inhibiting the lipid peroxidation, improving the membrane microflow, and lessening the Ca²⁺ concentration. With flow-cytometric technique, we demonstrated that 10-60 mg•L¯¹ Tet could concentration-dependently accelerate the G1 phase cells transforming to S phase cells, and increase the level of DNA in the S phase and protein in the G1, G2 phase cells significantly. Further studies indicated that the effect of Tet in promoting hepatocytes proliferation was not related to blockade of Ca²⁺ influx[24].

Tet could significantly reduce the degree of experimental hepatic fibrogenesis induced by CCl₄ in rats; the levels of serum hyaluronic acid and procollagen peptide were decreased, and the liver dysfunction was ameliorated, Tet could also obviously inhibit extracellular matrix formation and collagen deposition. In the liver tissue of rats treated with Tet, hepatic stellate cell (HSC) activation, proliferation, and transformation were down-regulated; the number of desmin-positive cells were reduced significantly. The anti-fibrotic effect of Tet had no significant difference from that of colchicine[25]. HSC activation, proliferation, and transforming into fibroblast are the putative events in hepatic fibrogenesis. Tet could significantly inhibit conventional cultured HSC activation and type I and type III collagen mRNA expressions and protein synthesis were down-regulated. Tet could block HSC proliferation colla gen synthesis induced by platelet-derived growth factor (PDGF), reduce the level of PDGF, PDGF receptor (PDGF-R beta1), transforming growth factor beta1 (TGF beta1) and alpha-smooth muscle actin mRNA, and also down-regulate the au tocrine of PDGF, PDGF-R beta1, TGF beta1. These data suggest that Tet may block hepatic fibrogenesis directly and/or through inhibiting cytokine expressions[26,27]. After taking Tet orally for three months, liver functions of the patients with cirrhosis were obviously improved. Administration Tet for six to eighteen months, serum levels of PIIIP and HA of the patients were markedly reduced. Histological examination showed that, compared with pretreatment or placebo, inflammatory cell infiltration was reduced, and even abolis hed, and that the deposition of ECM, type Iand type III collagen were decrea sed significantly[28].

Portal hypertension is one of important manifestations of the patients with cirrhosis. Upper gastrointestinal hemorrhage caused by portal hypertension commonly led to the patient’s death. After injecting Tet intravenously (2.0, 6.0 and 20.0 mg•kg¯¹), portal venous pressure and mean arterial pressure were assessed in cirrhotic rats induced by CCl₄. The results demonstrated that Tet induced dose-dependent decreases in portal venous pressure and mean arterial pressure. The maximum percentage reductions of portal venous pressure after Tet in the three different dosages were 5.4% ± 1.0%, 9.2% ± 0.8%, and 23.7% ± 1.2% of baseline, respectively. Total peripheral resistance was also reduced by Tet[29,30]. In portal hypertensive rats induced by partial portal vein ligation, Tet (4, 8, 16 and 24 mg•kg¯¹) induced dose-dependent decreases of portal venous pressure and mean arterial pressure after intravenous infusion. Tet (16 mg•kg¯¹) caused the portal venous pressure decreasing from a baseline of 12.5 mmHg to 10.0 mmHg, and the mean arterial pressure from a baseline of 90 mmHg to 80 mmHg. At 24 mg•kg¯¹, Tet reduced portal venous pressure and mean arterial pressure to 20.3% ± 2.4% and 28.4% ± 1.4% of baseline, resp ectively[31]. The effects of Tet on portal hypotension may be attributed to its actions of blocking voltage- and receptor-operated Ca²⁺ channels in vascular smooth muscle cells, inhibiting intracellular Ca²⁺ mobilization and dilating peripheral blood vessels. We had previously observed its clinical therapeutic effects on portal hypertension. Taking Tet orally for 2 consecutive years, the esophageal variceal pressure and the portal blood flow in cirrhotic patients with portal hypertension were significantly reduced. The proportion of patients with no recurrent gastrointestinal bleeding during 2 years’ medication of tetrandrine was 87.9%. It is suggested that Tet would be effective for cirrhotic patients with portal hypertension in preventing recurrent variceal bleeding[32].

Portal hypertensive gastropathy is caused by dysfunction of submucosal circulation and gastric mucosal barrier damage. Recent studies found that Tet increased prostgalandin E2, GMBE and GAM secretion, reduced the degree of gastric mucosa injury, and lowered the portal pressure. This result indicates that Tet may be useful in portal hypertensive gastropathy.

Pancreatic islet beta cells could be damaged by alloxan (50 mg•kg¯¹ i.v.) in rats, and diabetic animal models were thus prepared. Pancreatic islet beta cells density in experimental groups pretreated with Tet (100 mg•kg¯¹via gavage) at 1.5 h and 5 h prior to alloxan injection increased from the control value of 13 ± 4 to 62 ± 9 and 65 ± 7 (P ＜ 0.001). When the doses of Tet decreased from 100 mg•kg¯¹ to 50 mg•kg¯¹ and 25 mg•kg¯¹, the pancreatic islet beta cell density were 45 ± 5 and 38 ± 4 (P ＜ 0.01 and P ＜ 0.001)[33].